CORNERSTONE THERAPEUTICS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-12-20: Form 8-K; Period of report 2012-12-14; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2012-11-13: Form 8-K; Period of report 2012-11-06; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2012-11-09: Form 8-K; Period of report 2012-11-05; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2012-11-08: Form 8-K; Period of report 2012-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-12-20 | 8-K | 2012-12-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_46724.htm |
| 2012-11-13 | 8-K | 2012-11-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d437589d8k.htm |
| 2012-11-09 | 8-K | 2012-11-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 5, 2012, the Board of Directors (the “Board”) of Cornerstone Therapeutics Inc. (the “Company”) appointed Alastair McEwan as the Company’s Chief Financial Officer, effective November 6, 2012. | htm_46419.htm |
| 2012-11-08 | 8-K | 2012-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2012, Cornerstone Therapeutics Inc. (the “Company”) announced its financial results for the three and nine months ended September 30, 2012. | d435981d8k.htm |
| 2012-10-23 | 8-K | 2012-10-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 19, 2012, Cornerstone Therapeutics Inc. (the “Company”) and Vincent T. Morgus, the Company’s former Executive Vice President and Chief Financial Officer, entered into a Separation Letter Agreement and General Release (the “Separation Agreement”), approved by the Compensation Committee of the Company’s Board of Directors. | htm_46256.htm |
| 2012-10-19 | 8-K/A | 2012-06-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 5, 2012, Alessandro Chiesi notified the board of directors (the “Board”) of Cornerstone Therapeutics Inc. (the “Company”) of his resignation as a director from the Board, effective June 6, 2012. | htm_46239.htm |
| 2012-10-19 | 8-K/A | 2011-12-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 1, 2011, the Board of Directors (the “Board”) of Cornerstone Therapeutics Inc. (the “Company”) appointed James Harper to serve as a director, effective immediately. | htm_46238.htm |
| 2012-10-18 | 8-K | 2012-10-18 | 7.01 Regulation FD Disclosure | 7.01 On October 12, 2012, the U.S. Food and Drug Administration (the "FDA") approved the New Drug Application by Chiesi Farmaceutici S.p.A, Cornerstone Therapeutics Inc.’s (the "Company") majority stockholder, for Bethkis®, an inhaled tobramycin-based product indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa (the "Product"). | htm_46221.htm |
| 2012-09-28 | 8-K | 2012-09-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 24, 2012, Cornerstone Therapeutics Inc. (the "Company") notified Vincent T. Morgus, the Company’s Executive Vice President, Chief Financial Officer and Treasurer, that the Company had determined to exercise its rights under its employment agreement with Mr. Morgus to terminate Mr. Morgus’s employment. | htm_46103.htm |
| 2012-09-07 | 8-K/A | 2012-06-21 | 9.01 Financial Statements and Exhibits | 9.01 The audited consolidated financial statements of EKR Holdings, Inc. as of December 31, 2011 and 2010 and for each of the three years ended December 31, 2011, 2010 and 2009 are filed as Exhibit 99.1 and incorporated by reference. | d407270d8ka.htm |
| 2012-08-09 | 8-K | 2012-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2012, Cornerstone Therapeutics Inc. (the “Company”) announced its financial results for the three and six months ended June 30, 2012. | d392608d8k.htm |
| 2012-06-27 | 8-K | 2012-06-21 | 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders | 2.01 On June 26, 2012, Cornerstone Therapeutics Inc. (the “Company”), through its wholly owned subsidiary, Stone Acquisition Sub, Inc. (the “Merger Sub”), consummated its acquisition of EKR Holdings, Inc. (“EKR”), pursuant to an Agreement and Plan of Merger by and among the Company, the Merger Sub, EKR and EKR Therapeutics, Inc., a wholly owned subsidiary of EKR, dated May 14, 2012, as amended on June 26, 2012 (as amended, the “Merger Agreement”). 2.03 On June 21, 2012, the Company entered into a senior secured term loan facility (the “Facility”) with Chiesi, a related party, pursuant to a credit agreement (the “Credit Agreement”) between the Company and Chiesi executed on June 21, 2012. 3.02 The disclosure relating to the Facility (including the Conversion Option) set forth under Item 2.03 is hereby incorporated by reference into this Item 3.02. 3.03 The disclosure relating to the restrictions on declaring dividends on the Company’s common stock set forth under Item 2.03 is hereby incorporated by reference into this Item 3.03. | d371552d8k.htm |
| 2012-06-11 | 8-K | 2012-06-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 5, 2012, Alessandro Chiesi notified the board of directors (the "Board") of Cornerstone Therapeutics Inc. (the "Company") of his resignation as a director from the Board, effective June 6, 2012. | htm_45335.htm |
| 2012-05-24 | 8-K | 2012-05-22 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 22, 2012, the Company held its 2012 Annual Meeting of Stockholders to (i) elect nine members to the Board of Directors to serve as directors until the sooner of the election and qualification of their successors or the next annual meeting of stockholders and (ii) ratify the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012. | d355004d8k.htm |
| 2012-05-17 | 8-K | 2012-05-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d353968d8k.htm |
| 2012-05-15 | 8-K | 2012-05-14 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On May 15, 2012, Cornerstone Therapeutics Inc. (the “Company”) announced its financial results for the three months ended March 31, 2012. 8.01 On May 14, 2012, the Company and EKR Therapeutics, Inc. (“EKR Therapeutics”), a wholly owned subsidiary of EKR Holdings, Inc. (together with EKR Therapeutics, “EKR” ), announced that they had entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which the Company will acquire EKR. | d354618d8k.htm |
| 2012-03-27 | 8-K | 2012-03-21 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 Following a competitive process undertaken by the Audit Committee (the "Audit Committee") of the Board of Directors of Cornerstone Therapeutics Inc. (the "Company"), on March 21, 2012, the Company dismissed Grant Thornton LLP ("Grant Thornton") as the Company’s independent registered public accounting firm and engaged Ernst & Young LLP ("Ernst & Young") as its independent registered public accounting firm for the fiscal year ending December 31, 2012. | htm_44598.htm |
| 2012-03-16 | 8-K/A | 2011-12-28 | 9.01 Financial Statements and Exhibits | 9.01 The audited consolidated financial statements of Cardiokine, Inc. as of and for the years ended December 31, 2008 and 2009 are filed as Exhibit 99.1 and incorporated by reference. | d315516d8ka.htm |
| 2012-03-13 | 8-K | 2012-03-07 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_44515.htm |
| 2012-03-08 | 8-K | 2012-03-08 | 2.02 Results of Operations and Financial Condition | 2.02 On March 8, 2012, Cornerstone Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the fourth quarter and year ended December 31, 2011. | d312004d8k.htm |
| 2012-01-12 | 8-K/A | 2011-12-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 1, 2011, the Board of Directors (the “Board”) of Cornerstone Therapeutics Inc. (the “Company”) appointed James Harper to serve as a director, effective immediately. | htm_43965.htm |
| 2012-01-04 | 8-K | 2011-12-28 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets | 1.01 Entry into a Material Definitive Agreement. 2.01 On December 28, 2011, Cornerstone Therapeutics Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company; Cohesion Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”); Cardiokine, Inc., a Delaware corporation (“Cardiokine”); and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the indemnification representative of the Cardiokine stockholders. | d276351d8k.htm |